Acer Therapeutics 将来の成長

Future 基準チェック /56

Acer Therapeuticsは、66.2%と50.8%でそれぞれ年率66.2%で利益と収益が成長すると予測される一方、EPSはgrowで70.9%年率。

主要情報

66.2%

収益成長率

70.9%

EPS成長率

Pharmaceuticals 収益成長	23.7%
収益成長率	50.8%
将来の株主資本利益率	n/a
アナリストカバレッジ	Low
最終更新日	05 Sep 2023

今後の成長に関する最新情報

Recent updates

Acer Therapeutics to develop ACER-801 for post-traumatic stress disorder treatment

Oct 05

Acer, Relief's metabolic disorder therapy ACER-001 gets orphan drug status in EU

Aug 12

FDA accepts Acer's resubmitted U.S. marketing application for urea cycle disorder therapy

Jul 28

Need To Know: Acer Therapeutics Inc. (NASDAQ:ACER) Insiders Have Been Buying Shares

Feb 25

Acer Therapeutics completes enrollment in ACER-001 bioequivalence trial for urea cycle disorders

Dec 22

業績と収益の成長予測

OTCPK:ACER - アナリストの将来予測と過去の財務データ ( )USD Millions
日付	収益	収益	フリー・キャッシュフロー	営業活動によるキャッシュ	平均アナリスト数
12/31/2025	110	28	N/A	N/A	1
12/31/2024	48	4	N/A	N/A	2
12/31/2023	9	-22	N/A	N/A	2
6/30/2023	N/A	-39	-32	-32	N/A
3/31/2023	N/A	-33	-36	-36	N/A
12/31/2022	N/A	-26	-30	-30	N/A
9/30/2022	0	-21	-23	-23	N/A
6/30/2022	0	-20	-22	-22	N/A
3/31/2022	0	-20	-6	-6	N/A
12/31/2021	1	-15	0	0	N/A
9/30/2021	1	-17	-3	-3	N/A
6/30/2021	1	-20	1	1	N/A
3/31/2021	1	-23	-9	-9	N/A
12/31/2020	N/A	-23	-17	-17	N/A
9/30/2020	N/A	-22	-17	-17	N/A
6/30/2020	N/A	-21	-20	-20	N/A
3/31/2020	N/A	-26	-25	-25	N/A
12/31/2019	N/A	-29	-30	-30	N/A
9/30/2019	N/A	-33	-30	-30	N/A
6/30/2019	N/A	-31	-28	-27	N/A
3/31/2019	N/A	-25	-23	-23	N/A
12/31/2018	N/A	-21	-17	-17	N/A
9/30/2018	N/A	-17	-16	-16	N/A
6/30/2018	N/A	-17	-17	-17	N/A
3/31/2018	N/A	-15	-15	-15	N/A
12/31/2017	N/A	-14	-14	-14	N/A
9/30/2017	N/A	-12	-12	-12	N/A
6/30/2017	N/A	-11	-9	-9	N/A
3/31/2017	N/A	-9	N/A	-9	N/A
12/31/2016	N/A	-7	N/A	-7	N/A

アナリストによる今後の成長予測

収入対貯蓄率: ACERは今後 3 年間で収益性が向上すると予測されており、これは貯蓄率 ( 2.2% ) よりも高い成長率であると考えられます。

収益対市場: ACER今後 3 年間で収益性が向上すると予想されており、これは市場平均を上回る成長と考えられます。

高成長収益: ACER今後 3 年以内に収益を上げることが予想されます。

収益対市場: ACERの収益 ( 50.8% ) US市場 ( 8.9% ) よりも速いペースで成長すると予測されています。

高い収益成長: ACERの収益 ( 50.8% ) 20%よりも速いペースで成長すると予測されています。

一株当たり利益成長率予想

将来の株主資本利益率

将来のROE: ACERの自己資本利益率が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です

Acer Therapeutics 将来の成長

Future 基準チェック /56

主要情報

今後の成長に関する最新情報

Consensus forecasts updated

Consensus revenue estimates fall by 29%

No longer forecast to breakeven

Consensus forecasts updated

Consensus revenue estimates increase to US$8.00m

Recent updates

Acer Therapeutics Inc. Files Form 15

Acer Therapeutics Inc. Announces Executive Changes

Nasdaq to Delist the Securities of Acer Therapeutics

Acer Therapeutics Inc. announced delayed 10-Q filing

Acer Therapeutics Inc. announced delayed 10-Q filing

Acer Therapeutics Inc.(OTCPK:ACER) dropped from S&P TMI Index

Zevra Therapeutics, Inc. (NasdaqGS:ZVRA) entered into definitive Agreement to acquire Acer Therapeutics Inc. (NasdaqCM:ACER) for $91 million.

Acer Therapeutics Receives a Letter from Nasdaq Indicating the Company Is Not in Compliance with the $1.00 Minimum Bid Price Requirement Set in Nasdaq Listing Rule 5550(a)(2) for Continued Listing on the Nasdaq Capital Market

Acer Therapeutics Inc. Receives Non-Compliance Notice From Nasdaq

Acer Therapeutics Announces Full Enrollment of Phase 2A Trial of Acer-801 (Osanetant) for Treatment of Moderate to Severe Vasomotor Symptoms Associated with Menopause

Acer Therapeutics Inc. Announces Initiation of Two Investigator-Sponsored Trials of ACER-801 (Osanetant) in Men with Adenocarcinoma of the Prostate

Acer Therapeutics Compliant with All Nasdaq Listing Criteria

Acer Therapeutics Inc. announced that it has received $1.5 million in funding

Third quarter 2022 earnings released: US$0.31 loss per share (vs US$0.23 loss in 3Q 2021)

Insufficient new directors

Acer Therapeutics Receives Notice of Allowance of Key US Patent Application Covering EDSIVO™ (celiprolol)

Acer Therapeutics Inc. Announces Receipt of Notice of Allowance of US Patent Application Covering Kit Comprising Phenylbutyrate and Sodium Benzoate

Acer Therapeutics Inc. Announces Expansion of Acer-801 (Osanetant) Development Indications to Include Post-Traumatic Stress Disorder

Acer Therapeutics to develop ACER-801 for post-traumatic stress disorder treatment

First half 2022 earnings released: US$0.80 loss per share (vs US$0.54 loss in 1H 2021)

RELIEF THERAPEUTICS Holding SA and Acer Therapeutics Inc. Announce That the European Commission Has Granted Orphan Drug Designation for Acer-001 in Maple Syrup Urine Disease

Acer, Relief's metabolic disorder therapy ACER-001 gets orphan drug status in EU

Acer Therapeutics and Relief Therapeutics Announce FDA Acceptance for Review of NDA Resubmission for ACER-001 for Treatment of UCDs

FDA accepts Acer's resubmitted U.S. marketing application for urea cycle disorder therapy

Acer resubmits U.S. marketing application for urea cycle disorder therapy

Acer Therapeutics Inc. Resubmittes the ACER-001 New Drug Application (NDA) to the FDA for the Treatment of Urea Cycle Disorders

Acer Therapeutics Announces Initiation of its Pivotal Phase 3 DiSCOVER Trial of EDSIVO™ (celiprolol) for the Treatment of Vascular Ehlers-Danlos Syndrome

Acer Therapeutics and Relief Therapeutics Announce Update on U.S. FDA Review of New Drug Application for ACER-001

Acer Therapeutics Not Yet Received Decision from the U.S. Food and Drug Administration on ACER-001

Acer Therapeutics Receives a Letter from the Listing Qualifications Department Staff of the Nasdaq Stock Market Regarding Minimum Market Value of Listed Securities

Consensus forecasts updated

First quarter 2022 earnings: EPS and revenues miss analyst expectations

Acer Therapeutics Inc. Provides an Update on the Recent Corporate Developments

Acer Therapeutics Announces Agreement with FDA on Special Protocol Assessment for its Phase 3 EDSIVO™ (celiprolol) Trial in Vascular Ehlers-Danlos Syndrome Patients

Acer Therapeutics Inc. and Relief Therapeutics Holding AG Announce Presentation of Acer-001 Data At the Genetic Metabolic Dieticians International Conference

Insufficient new directors

Acer Therapeutics Inc., Annual General Meeting, May 20, 2022

Acer Therapeutics Inc. and Relief Therapeutics Announce Presentation of ACER-001 Data at the Society for Inherited Metabolic Disorders Annual Meeting

Acer Therapeutics’ EDSIVO Granted FDA Breakthrough Therapy Designation for Vascular Ehlers-Danlos Syndrome

Acer Therapeutics Regains Compliance with Nasdaq Listing Standard

Acer Therapeutics Enrolls First Patient in Its Phase 2A Clinical Trial of Acer-801 for Treatment of Moderate to Severe Vasomotor Symptoms Associated with Menopause

Consensus revenue estimates fall by 29%

Acer Therapeutics Inc. Announces Appointment of Adrian Quartel as Chief Medical Officer

Companies Like Acer Therapeutics (NASDAQ:ACER) Can Afford To Invest In Growth

No longer forecast to breakeven

Acer Therapeutics Inc. Announces ACER-801 IND Clearance for the Treatment of Induced Vasomotor Symptoms

Acer Therapeutics: Deriving Value By Developing Therapies For Rare Diseases

Consensus forecasts updated

Acer Therapeutics Plans Clinical Trial for Edsivo Following Type B FDA Meeting

Acer Expands Its Predator Gaming Portfolio with Three New HDR Monitors

Acer Therapeutics Plans NDA Submission for Acer-001 in Third Quarter 2021 Following Pre-NDA Meeting with FDA

Consensus revenue estimates increase to US$8.00m

We're Not Very Worried About Acer Therapeutics' (NASDAQ:ACER) Cash Burn Rate

Acer Therapeutics Inc. Announces Update on Settlement of Derivative Suits

Need To Know: Acer Therapeutics Inc. (NASDAQ:ACER) Insiders Have Been Buying Shares

Acer Therapeutics Inc. Announces Topline Results from its Bioequivalence Trial of ACER-001 Compared to BUPHENYL® Under Fed Conditions

Relief Therapeutics and Acer Therapeutics Sign Option Agreement to Pursue a Potential Collaboration and License Arrangement for the Worldwide Development and Commercialization of ACER-001 for the Treatment of Urea Cycle Disorders and Maple Syrup Urine Disease

New 90-day high: US$3.85

Acer Therapeutics completes enrollment in ACER-001 bioequivalence trial for urea cycle disorders

Acer Therapeutics Inc. Announces Publication of Additional Long-Term Data from COL3A1-Positive Vascular Ehlers-Danlos Syndrome (vEDS) Patients

New 90-day low - US$2.44

New 90-day high - US$5.41

Acer Therapeutics Inc. announced that it expects to receive $0.857493 million in funding

Acer Therapeutics Inc.(NasdaqCM:ACER) dropped from Russell 2000 Dynamic Index

Acer Therapeutics Inc.(NasdaqCM:ACER) dropped from Russell Small Cap Completeness Index

Acer Therapeutics Inc.(NasdaqCM:ACER) dropped from Russell Microcap Index

業績と収益の成長予測

アナリストによる今後の成長予測

一株当たり利益成長率予想

将来の株主資本利益率